Ondine Biomedical Reports Robust Growth in H1 2024
ONDINE BIOMEDICAL INC.
("Ondine Biomedical", "Ondine" or the "Company")
Ondine Biomedical Reports Robust Growth in H1 2024
Unaudited results for the six months to 30 June 2024
Ondine Biomedical Inc. (AIM:OBI), a leading provider of light-activated antimicrobial technology to prevent and treat hospital infections, is pleased to announce strong operational results for the first half of 2024, highlighting significant progress and expansion in its commercial and clinical endeavors.
Financial figures throughout this interim report are in Canadian dollars unless otherwise specified.
Operational Highlights
· Commercial growth: Adoption of the Company's novel light-activated antimicrobial, Steriwave®, increased by 190% to 29 hospitals by the end of H1 2024 (H1 2023: 10 Hospitals). Commenced commercial roll-out of the 2nd generation Nasal Illuminator in Canada post-period.
· Strategic partnership: Following the end of H1 2024, the Company announced a strategic partnership with Mölnlycke Health Care, a world-leading MedTech company that specializes in innovative solutions for wound care and surgical procedures, to bring Ondine's Steriwave nasal decolonization technology to the UK, EU, and Middle Eastern markets.
· Clinical trial progress: In June, the Clinical trial agreement for the US Phase 3 trial was signed with HCA Healthcare (HCA). Ondine, HCA and the contract research organization are collaboratively finalizing the details and site selection for the trial.
· Advancing into ICU: As previously announced, the Company accelerated plans to pursue the large and critical ICU market, and has partnered with the Royal Columbian Hospital Foundation's Advancing Innovation in Medicine (AIM) division to study Steriwave in intensive care units (ICU).
Financial Highlights
· Revenue of $0.9 million, reflecting a 101% increase compared to $0.4 million in H1 2023.
· Gross margin at 62%, up 300 basis points from 59% in H1 2023.
· Loss from operations of $7.8 million (H1 2023: $8.0 million).
· Cash, cash equivalents and restricted cash of $1.4 million as at 30 June 2024 (31 December 2023: $3.1 million).
· Secured c.$11 million of capital in support of commercial growth and general operations comprised of $6 million in May 2024 and a post-period private placement of $5 million to be delivered on or before 8 November 2024.
· Financial support of $0.7 million from Founder and CEO Carolyn Cross was received on an interest free, unsecured basis along with commitment for continued working capital support on similar terms while the Company secures additional long-term finance.
Carolyn Cross, CEO:
"Our significant revenue growth and expanded hospital adoption of Steriwave are testaments to the technology's efficacy as well as the need for simple solutions to prevent complex hospital infections. The Mölnlycke partnership underscores the value we bring to healthcare systems and marks a new era of accelerated growth for Ondine as we pursue approval for the large US market and expansion into critical care settings. We are excited about the road ahead and continued momentum in the second half of 2024."
Live Presentation
Ondine will be hosting a presentation to all existing and potential shareholders at 16:30 BST (08:30 Pacific time) held via the Investor Meet Company platform. Questions can be submitted at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet ONDINE BIOMEDICAL INC. via: https://www.investormeetcompany.com/ondine-biomedical-inc/register-investor
Investors who already follow ONDINE BIOMEDICAL INC. on the Investor Meet Company platform will automatically be invited.
Related Party Transaction
On 30 September Carolyn Cross provided a loan (the "Loan") of C$400,000 to the Company for additional working capital ahead of securing longer term financing. This is in addition to the C$285,000 loan provided on 11 September 2024. The Loan is deemed to constitute a related party transaction for the purpose of AIM Rule 13. The Company's Independent Directors, having consulted with Singer Capital Markets, the Company's nominated adviser, consider that the terms of the Loan are fair and reasonable insofar as Shareholders are concerned.
As previously announced, Carolyn and Robert Cross, who jointly own 49.5% of the Company, have indicated they will continue to support the Company with short term financing on similar favourable terms to extend the runway while the Company secures longer term financing.
Enquiries:
|
Ondine Biomedical Inc. |
|
|
Carolyn Cross, CEO |
+1 (604) 665 0555 |
|
|
|
|
Singer Capital Markets (Nominated Adviser and Joint Broker) |
|
|
Phil Davies, Sam Butcher
|
+44 (0)20 7496 3000 |
|
|
|
|
RBC Capital Markets (Joint Broker) |
|
|
Rupert Walford, Kathryn Deegan |
+44 (0)20 7653 4000 |
|
|
|
|
Vane Percy & Roberts (Media Contact) |
|
|
Simon Vane Percy, Amanda Bernard |
+44 (0)77 1000 5910 |
About Ondine Biomedical Inc.
Ondine Biomedical Inc. is a clinical Canadian life sciences company and leader in light-activated antimicrobial therapies (also known as 'photodisinfection'). Ondine has a pipeline of investigational products, based on its proprietary photodisinfection technology, in various stages of development.
Ondine's nasal photodisinfection system has a CE mark in Europe and the UK and is approved in Canada and several other countries under the name Steriwave®. In the US, it has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA and is currently undergoing clinical trials for regulatory approval. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns and other indications.
Chief Executive Officer's Statement
The first half of 2024 has been productive for Ondine, marked by robust growth and significant commercial advancements. Our continued progress is a direct reflection of the dedication and hard work of our team, our supporters and shareholders, as well as the trust placed in us by the healthcare professionals we serve.
Commercial Traction
Our recent commercial traction and rapid new hospital adoption rate have led to our strategic partnership with Mölnlycke Health Care, a global leader in the wound care and infection control industry, announced on 23 September 2024. This partnership will help to accelerate adoption of Steriwave in key markets, starting initially with the United Kingdom, which has a total addressable market of over 3 million major surgeries annually[1] and over 200,000 annual intensive care unit (ICU) admissions.[2]
Successful outcomes in initial hospital deployments continue to fuel adoption growth in our target markets of Canada and the UK. We grew the number of hospitals which are using, or have approved use of, Steriwave to 29 (190% increase year-over-year) and doubled our revenues compared to the same period last year. We are now deployed in five of Canada's 10 largest hospitals and aim to be in 9 of 10 of Canada's largest hospitals by the end of next year.
This year Ondine made significant inroads into the UK's National Health Service (NHS), in addition to our existing sales into the HCA UK network. In June, Steriwave became the first light-activated antimicrobial therapy to be listed on the NHS Supply Chain, the online procurement system which simplifies the purchasing process for NHS hospitals and clinics across England and Wales.
Following a successful initial pilot program, Ondine signed its first commercial contract with Mid Yorkshire Teaching NHS Trust - the first of the NHS Trusts to officially adopt universal nasal decolonization for presurgical patients. Mid Yorkshire Teaching NHS Trust accelerated its adoption of Steriwave into 2 hospitals, Pinderfields and Pontefract Hospitals, as standard of care. In a collaboration with Health Innovation Yorkshire & Humber and the York Health Economics Consortium (YHEC), data from the Mid Yorkshire hospitals is being used to conduct a health economic analysis of Steriwave. The findings, expected in the fourth quarter, should help to support further adoption into hospitals across the NHS Trusts in light of the NHS long term goals of innovative solutions to address antimicrobial resistance, reduced costs and improved patient outcomes.
Clinical Advancements
With the clinical trial and CRO agreements signed, and work progressing on site selections and finalizing details with principal investigators, we are poised to initiate our US Phase 3 trial with HCA Healthcare once the necessary funding is obtained, a key steppingstone to access the large US market. This trial, to be conducted at 14 HCA hospitals, will compare standard-of-care infection prevention practices with, and without, Steriwave nasal decolonization. The primary endpoint of this 5,000-patient trial is the reduction of surgical site infections, one of the most prevalent healthcare-associated infections (HAI) that costs US healthcare billions of dollars annually. We are very pleased to have esteemed Dr. Ed Septimus - Professor of Internal Medicine, Texas A&M College of Medicine and Senior Lecturer at Harvard Medical School - as Co-Medical Monitor for this large US clinical study.
Another major application for Steriwave is in intensive care units (ICU), where 12-13% of patients suffer from hospital-acquired infections, significantly increasing length of stay, mortality, and costly burden to overstretched healthcare resources. Preventing these infections is a priority for hospitals and nasal decolonization for these high-risk patients is recommended in multiple guidelines, including from the Centers for Disease Control and Prevention (CDC), the World Health Organization (WHO), the Society for Healthcare Epidemiology of America (SHEA) and Infectious Diseases Society of America (IDSA), and the European Guidelines (ESCMID). We are, therefore, very pleased with our recently announced research collaboration with the Royal Columbian Hospital Foundation & Advancing Innovation in Medicine (AIM) division led by Dr Steven Reynolds in support of Steriwave's intensive care unit application. This collaboration sets the stage to unlock the expansive global ICU market, where nasal decolonization (using topical antibiotic ointments over 5 days) is already recognized as a key infection prevention strategy.
The purpose of this strategic initiative is to integrate Ondine's Steriwave into ICU infection control and workflow protocols to determine the impact of rapid broad spectrum nasal decolonization on ICU infection rates, length of stay and mortality rates. Commencing with a four-month feasibility phase with a minimum of 320 ICU patients at Royal Columbian Hospital (RCH), the initial research is aimed at optimizing workflow protocols and collecting vital data on enrolment rates and baseline infection metrics. Results from this initial phase will inform a larger multicenter study involving up to 2,000 ICU patients to assess pharmacoeconomics, infection prevention, and patient outcomes in critical care settings. The $855,000 pilot study, supported by the RCH Foundation, will be funded by Ondine through the issuance of equity, over four milestones.
Financial Performance
On the financial front, we are pleased that revenues more than doubled year-on-year while holding operating costs steady, offsetting increased costs related to Phase 3 clinical trial preparations with strategic cost-saving measures. Cost of goods sold continued to fall, further increasing gross margins to 62%, up 300 basis points from 59% in H1 2023.
We raised circa $11 million, including a successful financing of over $6 million in May and $5 million post-period in a private placement financing. Furthermore, Ondine has the working capital support of founders and substantial shareholders while currently exploring longer term funding options with our advisors, and we are confident in the ability to secure longer-term growth capital.
Outlook
2024 is proving to be a pivotal year for the Company with significant progress made on the commercial and clinical development fronts. Looking ahead, we have an exciting and challenging chapter before us, one that will very much define us in the years to come. We are ready.
On behalf of the Board and all the Ondine employees, we would like to thank our numerous supporters and shareholders for the many contributions that pave the way for our continued success.
Carolyn Cross
Chief Executive Officer
30 September 2024
Ondine Biomedical Inc.
Unaudited condensed consolidated interim statements of financial position
(In thousands of Canadian dollars)
|
|
Notes |
June 30, 2024 $ |
December 31, 2023 $ |
|
Assets |
|
|
|
|
Current assets |
|
|
|
|
Cash |
|
1,218 |
2,981 |
|
Restricted cash |
|
152 |
157 |
|
Accounts and other receivables |
4, 16 |
238 |
326 |
|
Inventory |
5 |
1,288 |
1,066 |
|
Prepaid expenses and deposits |
6 |
326 |
220 |
|
|
|
3,222 |
4,750 |
|
Non-current assets |
|
|
|
|
Property and equipment |
7 |
767 |
949 |
|
Other assets |
6 |
36 |
35 |
|
|
|
803 |
984 |
|
Total Assets |
|
4,025 |
5,734 |
|
Liabilities |
|
|
|
|
Current liabilities |
|
|
|
|
Accounts payable and other liabilities |
8, 16 |
3,440 |
3,108 |
|
Current portion of lease liability |
9 |
351 |
382 |
|
Current portion of warrant liability |
10 |
215 |
- |
|
|
|
4,006 |
3,490 |
|
Non-current liabilities |
|
|
|
|
Lease liability |
9 |
- |
159 |
|
|
|
- |
159 |
|
Total Liabilities |
|
4,006 |
3,649 |
|
Equity |
|
|
|
|
Share capital |
11 |
244,829 |
239,647 |
|
Contributed surplus |
|
10,528 |
10,258 |
|
Reserves |
|
18,758 |
18,244 |
|
Deficit |
|
(274,096) |
(266,334) |
|
Total Shareholders' Equity |
|
19 |
2,085 |
|
Total Liabilities and Shareholders' Equity |
|
4,025 |
5,734 |
Going concern - Note 1; Commitments and contingencies - Note 14; Subsequent events - Note 22
|
Approved on behalf of the Board:
|
|
|
|
|
"Carolyn Cross" |
|
"Jean Charest" |
|
The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.
Ondine Biomedical Inc.
Unaudited condensed consolidated interim statements of loss and comprehensive loss
(In thousands of Canadian dollars, except share and per share amounts)
|
For the six months ended June 30, |
|||
|
|
Notes |
2024 $ |
2023 $ |
|
Revenue |
13, 15 |
859 |
428 |
|
Cost of goods sold |
17 |
(330) |
(177) |
|
Gross margin |
|
529 |
251 |
|
Expenses |
18 |
|
|
|
General and administration |
|
4,272 |
4,747 |
|
Research and development |
|
3,301 |
2,185 |
|
Marketing and sales |
|
514 |
1,055 |
|
Depreciation and amortization |
7 |
272 |
294 |
|
|
|
8,359 |
8,281 |
|
Loss from operations |
|
(7,830) |
(8,030) |
|
|
|
|
|
|
Other income (expense) |
|
|
|
|
Government loan forgiveness |
|
- |
151 |
|
Accretion and interest expense |
|
(22) |
(20) |
|
Interest income |
|
- |
204 |
|
Loss on disposal of property and equipment |
|
- |
(95) |
|
Change in fair value of warrant liability |
|
112 |
- |
|
Other income (expense) |
|
(2) |
(5) |
|
Foreign exchange gain (loss) |
|
(20) |
(105) |
|
|
|
68 |
130 |
|
Net loss for the period |
|
(7,762) |
(7,900) |
|
Other comprehensive loss |
|
|
|
|
Exchange differences on translation of foreign operations (1) |
|
28 |
(16) |
|
Total comprehensive loss |
|
(7,734) |
(7,916) |
|
|
|
|
|
|
Net loss per share |
|
|
|
|
Basic and diluted |
|
(0.03) |
(0.04)) |
|
|
|
|
|
|
Weighted average number of shares outstanding |
|
|
|
|
Basic and diluted |
|
241,469,143 |
194,715,848 |
(1) May be reclassified to profit or loss in subsequent periods.
The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.
Ondine Biomedical Inc.
Unaudited condensed consolidated interim statements of changes in equity
(In thousands of Canadian dollars, except share amounts)
|
|
Number of common shares |
Share capital $ |
Contributed surplus $ |
Share-based payment reserve $ |
Currency translation reserve $ |
Accumulated Deficit $ |
Equity $ |
|
Balance, January 1, 2023 |
194,592,857 |
235,042 |
10,528 |
18,479 |
(483) |
(251,922) |
11,644 |
|
Issuance of share capital - Note 11 |
390,550 |
370 |
- |
(370) |
- |
- |
- |
|
Share-based payments - Note 12 |
- |
- |
- |
417 |
- |
- |
417 |
|
Total comprehensive loss for the period |
- |
- |
- |
- |
(16) |
(7,900) |
(7,916) |
|
Balance, June 30, 2023 |
194,983,407 |
235,412 |
10,528 |
18,526 |
(499) |
(259,822) |
4,145 |
|
Balance, January 1, 2024 |
226,753,789 |
239,647 |
10,528 |
18,726 |
(482) |
(266,334) |
2,085 |
|
Issuance of share capital upon financing - Note 10 |
50,531,970 |
5,732 |
- |
- |
- |
- |
5,732 |
|
Share issuance costs - Note 11 |
- |
(550) |
- |
- |
- |
- |
(550) |
|
Share-based payments - Note 12 |
- |
- |
- |
486 |
- |
- |
486 |
|
Total comprehensive loss for the period |
- |
- |
- |
- |
28 |
(7,762) |
(7,734) |
|
Balance, June 30, 2024 |
277,285,759 |
244,829 |
10,528 |
19,212 |
(454) |
(274,096) |
19 |
The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.
Ondine Biomedical Inc.
Unaudited condensed consolidated interim statements of cash flows
(In thousands of Canadian dollars)
|
|
For the six months ended June 30, |
||
|
|
Notes |
2024 $ |
2023 $ |
|
Cash flows from (used in) operating activities |
|
|
|
|
Net loss for the period |
|
(7,762) |
(7,900) |
|
Adjustments for non-cash items: |
|
|
|
|
Depreciation of right-of-use assets |
7 |
189 |
187 |
|
Depreciation and amortization of other property and equipment |
7 |
95 |
118 |
|
Accretion and interest expense |
|
22 |
20 |
|
Share-based payments |
12 |
486 |
417 |
|
Change in fair value of warrant liability |
10 |
(112) |
- |
|
Unrealized foreign exchange (gain) loss |
|
(21) |
111 |
|
Government loan forgiveness |
|
- |
(151) |
|
Loss on disposal of property and equipment |
|
- |
95 |
|
Other |
|
- |
24 |
|
Changes in non-cash working capital |
19 |
19 |
(1,095) |
|
Net cash used in operating activities |
|
(7,084) |
(8,174) |
|
Cash flows from (used in) financing activities |
|
|
|
|
Repayment of lease obligations |
|
(224) |
(171) |
|
Repayment of government loan |
|
- |
(40) |
|
Proceeds from public offering |
|
6,059 |
- |
|
Share issuance costs |
|
(550) |
- |
|
Net cash from financing activities |
|
5,285 |
(211) |
|
Cash flows used in investing activities |
|
|
|
|
Purchase of property and equipment |
7 |
(10) |
(174) |
|
Net cash used in investing activities |
|
(10) |
(174) |
|
Net decrease in cash and restricted cash |
|
(1,809) |
(8,559) |
|
Effect of foreign exchange rate change on cash and restricted cash |
|
41 |
(127) |
|
Cash and restricted cash, beginning of period |
|
3,138 |
13,272 |
|
Cash and restricted cash, end of period |
|
1,370 |
4,586 |
|
|
|
|
|
|
Supplemental cash flow information |
19 |
|
|
The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.
Ondine Biomedical Inc.
Unaudited condensed consolidated interim statements of cash flows
(In thousands of Canadian dollars)
Cash and restricted cash are comprised of:
|
|
For the six months ended June 30, |
||
|
|
|
2024 $ |
2023 $ |
|
Cash |
|
1,218 |
4,439 |
|
Restricted cash |
|
152 |
147 |
|
Cash, cash equivalents and restricted cash, end of period |
|
1,370 |
4,586 |
The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.
Ondine Biomedical Inc.
Notes to the Unaudited Condensed Consolidated Interim Financial Statements
Year ended December 31, 2023 and 2022
(In thousands of Canadian dollars, except as otherwise indicated)
1. Nature of operations and going concern
Ondine Biomedical Inc. (the "Company") was incorporated under the British Columbia Business Corporations Act on September 9, 1996. The Company is a biotechnology company engaged in the development and commercialization of innovative anti-infective therapies covering a broad spectrum of bacterial, fungal and viral infections primarily using antimicrobial photodynamic therapy ("aPDT") as a platform technology for its products, which are used as an alternative to the use of antibiotics. The Company's aPDT products employ laser-based activation of proprietary compounds to treat a wide range of medical infections. The address of the Company's corporate office is 888-1100 Melville Street, Vancouver, BC, Canada. The common shares of the Company are listed on the AIM Market of the London Stock Exchange under the symbol "OBI.L".
These unaudited condensed consolidated interim financial statements have been prepared on a going concern basis, which assumes the Company will be able to meet its obligations and continue its operations in the normal course of business for at least twelve months from June 30, 2024.
The Company has a history of incurring significant losses and as at June 30, 2024, had an accumulated deficit of $274,096 (December 31, 2023 - $266,334). As at June 30, 2024, the Company had a cash and cash equivalents balance of $1,218 (December 31, 2023 - $2,981) and a negative working capital balance of $784 (December 31, 2023 - positive $1,260). In the six months ended June 30, 2024, cash used in operating activities totaled $7,084 (June 30, 2023 - $ 8,174).
The Company's ability to continue as a going concern is dependent on its ability to develop profitable operations and/or to continue to obtain the necessary financing to meet its corporate expenditures and discharge its liabilities in the normal course of business. The Company will need to raise funds through public or private equity and/or debt financings. Although the Company has been successful in raising finance in the past there can be no assurance that it will be successful in the future. If the Company is unable to generate positive cash flows or obtain adequate financing, the Company may need to curtail operations. These factors give rise to material uncertainty that may cast significant doubt on the Company's ability to continue as a going concern. The consolidated financial statements do not give effect to adjustments to carrying values and to the classification of assets and liabilities that would be required if the Company were unable to continue as a going concern and such adjustments could be material.
2. Basis of preparation
(a) Statement of compliance
These unaudited condensed consolidated interim financial statements have been presented in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board ("IFRS Accounting Standards") as applicable to the preparation of consolidated financial statements, as set out in International Accounting Standard ("IAS") 34, Interim Financial Reporting. They do not include all the information required for a complete set of IFRS financial statements. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Company's financial position and performance since the last annual consolidated financial statements as at and for the year ended December 31, 2023.
The unaudited condensed consolidated interim financial statements were approved and authorized for issue by the Board of Directors on September 27, 2024.
(b) Basis of measurement
The unaudited condensed consolidated interim financial statements have been prepared on a historical cost basis as stated in the accounting policies. The expenses within the consolidated statements of loss and comprehensive loss are presented by function. Refer to Note 18 for details of expenses by nature.
(c) Use of estimates, assumptions and judgments
The preparation of unaudited condensed consolidated interim financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the amounts reported in the consolidated financial statements and accompanying disclosures. Although these estimates are based on management's knowledge of current events and actions the Company may undertake in the future, actual results may differ from the estimates and the differences may be material.
Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates, if any, are recognized in the year in which the estimates are revised and in any future years affected.
Information about the judgments, estimates and assumptions made by management in preparing these condensed consolidated interim financial statements are as described under "Basis of presentation - Judgments and estimates" in the Company's consolidated financial statements for the year ended December 31, 2023.
3. Material accounting policies
The accounting policies in these unaudited condensed consolidated interim financial statements are as described under "Material accounting policies" in the Company's consolidated financial statements for the year ended December 31, 2023.
4. Accounts and other receivables
|
|
|
June 30, 2024 $ |
December 31, 2023 $ |
|
Trade receivables |
|
232 |
324 |
|
Other receivables |
|
6 |
2 |
|
|
|
238 |
326 |
5. Inventory
|
|
|
June 30, 2024 $ |
December 31, 2023 $ |
|
Raw materials |
|
376 |
555 |
|
Work-in-progress |
|
- |
118 |
|
Finished goods |
|
912 |
393 |
|
|
|
1,288 |
1,066 |
During the six months ended June 30, 2024, raw materials, work-in-progress and finished goods included in cost of goods sold amounted to $318 (June 30, 2023 - $157). During the six months ended June 30, 2024 and 2023, inventory valued at $nil and $9, respectively, was written off and reflected within cost of goods sold.
6. Prepaids and deposits, and non-current assets
|
|
June 30, 2024 $ |
December 31, 2023 $ |
|
Prepaid insurances |
139 |
154 |
|
Lease deposits |
36 |
35 |
|
Other prepaid costs |
187 |
66 |
|
|
362 |
255 |
|
Less: Current portion of prepaid expenses and deposits |
326 |
220 |
|
Other non-current assets |
36 |
35 |
7. Property and equipment
The Company's property and equipment gross carrying amounts and accumulated depreciation were as follows:
|
|
Computer equipment $ |
Furniture and fixtures $ |
Lab and office equipment $ |
Leasehold improvements $ |
Manufacturing equipment and tools $ |
Demo equipment $ |
Right-of-use $ |
Total $ |
|
Cost |
|
|
|
|
|
|
|
|
|
Balance, January 1, 2023 |
291 |
246 |
472 |
292 |
781 |
164 |
1,086 |
3,332 |
|
Additions |
25 |
- |
62 |
25 |
65 |
- |
- |
177 |
|
Transfers and other |
- |
- |
- |
- |
- |
69 |
- |
69 |
|
Disposals and derecognition |
(176) |
(193) |
(275) |
- |
(512) |
- |
- |
(1,156) |
|
Exchange adjustment |
(6) |
(1) |
(11) |
(6) |
(11) |
- |
(21) |
(56) |
|
Balance, December 31, 2023 |
134 |
52 |
248 |
311 |
323 |
233 |
1,065 |
2,366 |
|
Additions |
3 |
- |
7 |
- |
- |
67 |
- |
77 |
|
Transfers and other |
- |
- |
- |
- |
- |
- |
- |
- |
|
Disposals and derecognition |
- |
- |
(10) |
- |
- |
- |
- |
(10) |
|
Exchange adjustment |
(6) |
1 |
8 |
9 |
11 |
2 |
31 |
66 |
|
Balance, June 30, 2024 |
141 |
53 |
253 |
320 |
334 |
302 |
1,096 |
2,499 |
|
Accumulated depreciation |
|
|
|
|
|
|
|
|
|
Balance, January 1, 2023 |
193 |
230 |
433 |
292 |
527 |
32 |
221 |
1,928 |
|
Additions |
46 |
3 |
36 |
8 |
72 |
47 |
375 |
587 |
|
Transfers and other |
- |
- |
- |
- |
- |
(7) |
- |
(7) |
|
Disposals and derecognition |
(158) |
(193) |
(271) |
- |
(435) |
(1) |
- |
(1,058) |
|
Exchange adjustment |
(4) |
1 |
(8) |
(5) |
(7) |
- |
(10) |
(33) |
|
Balance, December 31, 2023 |
77 |
41 |
190 |
295 |
157 |
71 |
586 |
1,417 |
|
Additions |
19 |
2 |
15 |
6 |
28 |
25 |
189 |
284 |
|
Transfers and other |
- |
- |
- |
- |
- |
- |
- |
- |
|
Disposals and derecognition |
- |
- |
(10) |
- |
- |
- |
- |
(10) |
|
Exchange adjustment |
2 |
(1) |
8 |
8 |
6 |
1 |
17 |
41 |
|
Balance, June 30, 2024 |
98 |
42 |
203 |
309 |
191 |
97 |
792 |
1,732 |
|
Net book value |
|
|
|
|
|
|
|
|
|
December 31, 2023 |
57 |
11 |
58 |
16 |
166 |
162 |
479 |
949 |
|
June 30, 2024 |
43 |
11 |
50 |
11 |
143 |
205 |
304 |
767 |
During the six months ended June 30, 2024, depreciation of $12 (June 30, 2023 - $11) was allocated to cost of goods sold, and $272 to operating expenses (June 30, 2023 - $294).
8. Accounts payable and other liabilities
|
|
|
June 30, 2024 $ |
December 31, 2023 $ |
|
Accounts payable |
|
1,884 |
1,363 |
|
Accrued liabilities |
|
1,375 |
1,605 |
|
Employee related payables |
|
108 |
69 |
|
Accrued interest |
|
73 |
71 |
|
|
|
3,440 |
3,108 |
9. Lease liability
|
|
|
|
Office spaces and facilities $ |
|
As at January 1, 2023 |
|
|
896 |
|
Interest accretion |
|
|
46 |
|
Lease payments |
|
|
(388) |
|
Exchange adjustment |
|
|
(13) |
|
As at December 31, 2023 |
|
|
541 |
|
As at January 1, 2024 |
|
|
541 |
|
Interest accretion |
|
|
18 |
|
Lease payments |
|
|
(224) |
|
Exchange adjustment |
|
|
16 |
|
As at June 30, 2024 |
|
|
351 |
|
|
|
June 30, 20224 $ |
December 31, 2023 $ |
|
Current portion |
|
351 |
382 |
|
Non-current |
|
- |
159 |
|
Total lease liability |
|
351 |
541 |
The Company's leases are for office spaces and a laboratory facility. The expense relating to variable lease payments not included in the measurement of lease obligations was $115 (June 30, 2023 - $86). This consists of variable lease payments for operating costs and property taxes. Total cash outflow for leases was $339 (June 30, 2023- $257), including $206 (June 30, 2023 - $150) of principal payments on lease obligations.
As at June 30, 2024, the minimum annual payments under these leases, including an estimate of operational costs for its office and laboratory premises based on current costs, is provided below.
|
|
$ |
|
2024 |
293 |
|
2025 |
232 |
|
|
525 |
10. Warrant liability
|
|
Units |
Amount $ |
|
Balance, December 31, 2023 |
- |
- |
|
Issued |
25,265,977 |
327 |
|
Fair value adjustment |
- |
(112) |
|
Balance, June 30, 2024 |
25,265,977 |
215 |
On May 9, 2024, as part of the Company's finance raise, 25,265,977 warrants were granted with an exercise price of GBP0.15 ($0.26) and an expiration date of February 9, 2025.
The fair value of warrants granted were estimated with the Black-Scholes model using the following assumptions at the time of grant on May 9, 2024:
|
Dividend yield |
0% |
|
Expected volatility |
92% |
|
Risk-free interest rate |
4.28% |
|
Expected life of options (years) |
0.8 |
|
Forfeiture rate |
0% |
Volatility was estimated by using the historical volatility of the Company's trading history and volatility history. The expected life in years represents the period of time that options granted are expected to be outstanding. The risk-free interest rate is based on Canadian government benchmark bonds with a term equal to or a remaining term that approximates the expected life of the warrants.
Issuance costs for the warrants of $31 were recorded in the Comprehensive Statements of Loss and Comprehensive Loss.
The fair value of the warrants were determined estimated with the Black-Scholes model using the following assumptions as at June 30, 2024:
|
Dividend yield |
0% |
|
Expected volatility |
78% |
|
Risk-free interest rate |
4.02% |
|
Expected life of options (years) |
0.6 |
|
Forfeiture rate |
0% |
As at June 30, 2024, warrants outstanding had a remaining contractual life of 0.6 years (June 30, 2023- nil).
11. Share capital
Common Stock
Authorized
An unlimited number of common shares without par value.
Issued
As at June 30, 2024, the Company's issued share capital consisted of 277,285,759 common shares (December 31, 2023 - 226,753,789).
On May 9, 2024, the Company issued 50,531,970 common shares at a price of GBP0.07 ($0.12). The Company incurred accounting, legal, advisory and disbursement costs of $550 directly related to the completion of the finance raise. The costs incurred were recorded to equity in the consolidated statement of financial position.
12. Share-based payments
(a) Stock Option Plan
On November 1, 2021, the Board of Directors approved and adopted an amended stock option plan for the Company which provides for the grant of stock options to directors, officers, employees and consultants from time to time at the discretion of the directors. Under the terms of the amended stock option plan, the maximum number of options authorized for issuance is 10% of the issued and outstanding common shares in any 10-year period for any employee' share scheme and the maximum number of options authorized for issuance is 5% of the issued and outstanding common shares in any 10-year period for any executive share scheme. As at June 30, 2024, the maximum number of total options that can be outstanding are 27,728,576 (December 31, 2023 - 22,675,379).
A summary of the status of the stock options outstanding is as follows:
|
|
June 30, 2024 |
December 31, 2023 |
||
|
|
Number of options
|
Weighted average exercise price $ |
Number of options
|
Weighted average exercise price $ |
|
Outstanding, beginning of period |
3,690,000 |
0.81 |
8,070,000 |
1.07 |
|
Options granted |
8,940,000 |
0.15 |
50,000 |
0.29 |
|
Options expired |
- |
- |
- |
- |
|
Options forfeited |
(86,250) |
0.46 |
- |
- |
|
Options cancelled |
(28,750) |
0.46 |
(75,000) |
0.90 |
|
Outstanding, end of period |
12,515,000 |
0.35 |
8,045,000 |
1.07 |
|
Exercisable, end of period |
1,795,000 |
0.82 |
4,785,000 |
1.11 |
Share-based payments expense for the six months ended June 30, 2024, in the amount of $486 (June 30, 2023 - $417) was recorded.
The outstanding options for the six months ended June 30, 2024 is as follows:
|
Exercise price |
Number of options |
Remaining life (years) |
|
$ 0.01 |
200,000 |
2.25 |
|
$ 0.15 |
8,940,000 |
4.58 |
|
$ 0.29 |
30,000 |
3.74 |
|
$ 0.36 |
310,000 |
3.44 |
|
$ 0.49 |
390,000 |
3.24 |
|
$ 0.90 |
1,070,000 |
1.88 |
|
$ 0.93 |
1,475,000 |
2.60 |
|
$ 3.00 |
100,000 |
2.05 |
|
$ 0.35 |
12,515,000 |
3.98 |
The fair value of stock options granted during the six months ended June 30, 2024 and 2023 were estimated with the Black-Scholes model using the following assumptions at the time of grant:
|
|
For the six months ended June 30, |
|
|
|
2024 |
2023 |
|
Dividend yield |
0% |
0% |
|
Annualized volatility |
81% |
76% |
|
Risk-free interest rate |
3.52% |
2.96% |
|
Expected life of options (years) |
5 |
5 |
|
Forfeiture rate |
11% |
14% |
Volatility was estimated by using the historical volatility of other companies that the Company considers comparable that have trading history and volatility history. The expected life in years represents the period of time that options granted are expected to be outstanding. The risk-free interest rate is based on Canadian government benchmark bonds with a term equal to or a remaining term that approximates the expected life of the options.
The weighted average fair value of stock options granted during the twelve months ended June 30, 2024, was $0.12 per option (June 30, 2023 - $0.18). As at June 30, 2024, stock options outstanding had a remaining contractual life of 3.98 years (June 30, 2023 - 2.11 years).
(b) Warrants
On May 30, 2020 and December 1, 2021, the Company granted warrants entitling the holders to acquire common shares of the Company as consideration for ongoing consulting and advisory services. A summary of the status of the warrants outstanding is as follows:
|
|
June 30, 2024 |
June 30, 2023 |
||
|
|
Number of warrants
|
Weighted average exercise price $ |
Number of warrants
|
Weighted average exercise price $ |
|
Outstanding, beginning of period |
2,295,845 |
1.08 |
2,295,845 |
1.08 |
|
Outstanding, end of year |
2,295,845 |
1.08 |
2,295,845 |
1.08 |
|
Exercisable, end of year |
2,295,845 |
1.08 |
2,295,845 |
1.08 |
The expense for the six months ended June 30, 2024 was $nil (June 30, 2023 - $nil). As at June 30, 2024, warrants outstanding had a remaining contractual life of 0.5 years (June 30, 2023- 1.5 years).
13. Related party transactions
(a) Revenues, product shipments and expenses
|
For the six months ended June 30, |
||
|
|
2024 $ |
2023 $ |
|
Product sales (i) |
20 |
- |
(i) Product sales for the six months ended June 30, 2024 were to a related company. The revenue associated with product shipments was not recognized due to revenue recognition conditions not being met, and the cost of the product shipped to a related company was included in cost of goods sold. The revenue associated with product shipments will be recognized in a subsequent year(s) upon invoice payment. For the six months ended June 30, 2024, there was $11 (June 30, 2023 - $5) of products shipped to a related party company for which revenue was not recognized.
(b) Compensation of key management personnel
The Company's key management personnel have the authority and responsibility for planning, directing and controlling activities of the Company and consists of the Company's executive officers and directors.
|
For the six months ended June 30, |
||
|
|
2024 $ |
2023 $ |
|
Compensation and other short-term benefits (i) |
721 |
98 |
|
Directors' fees (ii) |
271 |
327 |
|
Share-based payments (iii) |
195 |
52 |
|
Consulting expenses (iv) |
221 |
74 |
|
|
1,408 |
551 |
(i) During the six months ended June 30, 2023, the Company reassessed the initial estimates of the key managements' performance against the established criteria, leading to a change in estimate of the bonus accrual and reduced compensation and other short-term benefits by $625.
(ii) On May 9, 2024, as part of the Company's finance raise, directors' fees of $271 were paid in the form of Common Shares.
(iii) On January 25, 2024, the Company granted 5,815,000 stock options to key management personnel.
(iv) Expenses incurred for consulting services provided by companies under the control of an officer and a related party of the Company
(c) Related party balances
|
|
June 30, 2024 $ |
December 31, 2023 $ |
|
Included in warrant liability (i) |
17 |
- |
|
Included in accounts payable and other liabilities (ii) |
100 |
45 |
|
|
117 |
45 |
(i) On May 9, 2024, as part of the Company's finance raise, key management personnel received 2,039,989 warrants
(ii) Loans payable to related parties are due to the personal holding company of the Company's controlling shareholder. The loans payable to related parties are unsecured. The related party balances included in accounts payable and other liabilities consist of payables for services incurred to related parties
14. Commitments and contingencies
Open purchase order commitments as at June 30, 2024 were $1,521 (December 31, 2023 - $469) for the purchase of inventory and contracted development and clinical services.
The Company and its subsidiaries may, from time to time, be a party to certain legal disputes and claims arising from employment, environmental or commercial issues in the normal course of business. The Company has the following contingency at June 30, 2024:
(i) The Company's Barbadian subsidiary held intellectual property in Barbados until December 22, 2022. As a result of the Barbados Companies (Economic Substance) Act passed in 2019, the Barbadian subsidiary must comply with economic substance requirements set out in the legislation. If the Barbadian subsidiary cannot establish economic substance in Barbados, the Barbadian subsidiary could be subject to additional financial penalties and/or could be struck from the register of companies.
On December 22, 2022, the Company transferred the intellectual property from the Barbadian subsidiary to a new Swiss subsidiary via an intercompany sale at a fair value which was determined by an independent third party. Challenges from Barbadian, Swiss, Canadian or United States authorities regarding any of the foregoing, which results in an unfavorable outcome, could have a material impact on the financial position and operating results of the Company.
15. Segmented information
Management has determined that the Company has one reportable operating segment, aPDT products. This segment accounts for all of the Company's revenue, cost of goods sold and operating expenses. Determination of the operating segment was based on the level of financial reporting to the Company's chief operating decision makers. Revenues are attributed to the geographic area where the customer is located.
|
For the six months ended June 30, |
||
|
|
2024 $ |
2023 $ |
|
Product revenue |
|
|
|
Canada |
824 |
390 |
|
Other |
35 |
38 |
|
|
859 |
428 |
Revenue from significant customers are as follows:
|
For the six months ended June 30, |
||
|
|
2024 $ |
2023 $ |
|
Customer 1 |
316 |
290 |
|
Customer 2 |
212 |
11 |
|
Other |
331 |
127 |
|
|
859 |
428 |
A summary of non-current assets (excluding other assets) by geographical area based on the location of the asset is as follows:
|
|
June 30, $ |
December 31, 2023 $ |
|
Canada |
220 |
210 |
|
United States |
547 |
739 |
|
|
767 |
949 |
16. Financial risk management and financial instruments
All assets and liabilities for which fair value is measured or disclosed in the unaudited condensed consolidated interim financial statements are categorized within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:
Level 1 Unadjusted quoted market prices in active markets for identical assets or liabilities;
Level 2 Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable; and
Level 3 Valuation techniques for which the lowest level input that is significant to the fair value measurement is not based on observable market data.
As at June 30, 2024, the carrying values of cash, restricted cash, accounts and other receivables, and accounts payable and other liabilities approximate their fair values because of their nature, relatively short maturity dates.
Financial liabilities measured at fair value through profit or loss on a recurring basis include the warrant liabilities (Note 10) which are categorized as Level 2 fair value inputs.
(a) Management of risks arising from financial instruments
The overall responsibility for the establishment and oversight of the Company's risk management policies resides with the Board of Directors. The Company's risk management policies are established to identify, analyze and manage the risks faced by the Company and to implement appropriate procedures to monitor risks and adherence to established controls. Risk management policies and systems are reviewed periodically in response to the Company's activities and to ensure applicability. The Company, through its financial assets and liabilities, is exposed to certain risks as follows:
Credit risk
The Company is exposed to credit risk arising from the possibility that cash held, and accounts receivable are non-recoverable. However, the Company believes that its exposure to credit risk in relation to the cash and receivables is low. All of the cash held by the Company and its subsidiaries was held with reputable financial institutions. Since the majority of the Company's customers are considered to have low default risk and its historical default rate and frequency of losses are low, the lifetime expected credit loss allowance as at June 30, 2024 is shown in the table below. The Company's maximum exposure to credit risk is limited to the carrying amount of financial assets recognized as at June 30, 2024 and June 30, 2023 summarized below:
|
|
June 30, $ |
December 31, 2023 $ |
|
Classes of financial assets - carrying amounts |
|
|
|
Cash and cash equivalents |
1,218 |
2,981 |
|
Restricted cash |
152 |
157 |
|
Accounts receivable, net of credit loss allowance |
238 |
326 |
|
|
1,608 |
3,464 |
The aging of the Company's accounts receivable is as follows:
|
|
June 30, $ |
December 31, 2023 $ |
|
Trade accounts receivable, net of credit loss allowance |
|
|
|
Current |
212 |
231 |
|
Past due 1 to 30 days |
- |
39 |
|
Past due 31 to 60 days |
20 |
54 |
|
|
232 |
324 |
|
Other receivables |
6 |
2 |
|
|
238 |
326 |
The change in the Company's credit loss allowance for provision is as follows:
|
|
June 30, $ |
December 31, 2023 $ |
|
Balance - beginning of period |
903 |
864 |
|
Credit loss expense - net of reversals |
- |
9 |
|
Balance - end of period |
903 |
903 |
Foreign currency risk
The results of the Company's operations are subject to currency transaction and translation risks. The fair value of future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. The Company operates in Canada, the United States, the United Kingdom, Barbados, and Switzerland and is exposed to foreign exchange risk due to fluctuations in the US Dollar ("US$"), Great British Pound ("GBP"), Barbadian Dollar, and Swiss Franc against the Canadian dollar. Foreign exchange risk arises from financial assets and liabilities denominated in currencies other than the functional currency of the respective entities. The Company's primary risk is associated with fluctuations between the US$ and Canadian dollar, and the GBP and Canadian dollar.
The Company has determined that the effect of a 10% increase or decrease in the US$ and GBP against the Canadian dollar on net financial assets and liabilities, as at June 30, 2024, including cash, accounts receivables, accounts payable and other liabilities denominated in US$, and GBP would result in an increase or decrease of approximately $151 (June 30, 2023 - $261) in the unaudited condensed consolidated interim statements of loss and comprehensive loss for the six months ended June 30, 2024.
Interest rate risk
Interest rate risk is the risk that the fair values and future cash flows of the Company will fluctuate because of changes in market interest rates. The Company did not incur or have any other interest-bearing assets or liabilities.
Liquidity risk
Liquidity risk is the risk that the Company will not be able to meet its obligations as they fall due. The Company's objective is to ensure that there is sufficient liquidity to meet its short-term business requirements, taking into account its anticipated cash flows from operations and its holdings of cash. The Company's principal sources of liquidity are cash provided by operations, related party loans, debt and equity issuances. The Company projects and monitors its cash requirements to accommodate changes in liquidity needs (Note 1).
In addition to the commitments in Note 9, Note 10 and Note 14, the Company has the following contractual financial liabilities as at June 30, 2024:
|
|
Carrying amount $ |
Contractual cash flows $ |
Less than one year $ |
More than one year $ |
|
Financial liabilities |
|
|
|
|
|
Accounts payable and other liabilities |
3,440 |
3,440 |
3,440 |
- |
|
|
3,440 |
3,440 |
3,440 |
- |
17. Cost of goods sold
|
For the six months ended June 30, |
||
|
|
2024 $ |
2023 $ |
|
Inventory - Note 5 |
318 |
157 |
|
Inventory write-off - Note 5 |
- |
9 |
|
Depreciation - Note 7 |
12 |
11 |
|
|
330 |
177 |
18. Expenses by nature
General and administration, research and development, marketing and sales, and depreciation and amortization expenses are comprised of the following expenses by nature:
|
For the six months ended June 30, |
||
|
|
2024 $ |
2023 $ |
|
Salaries and benefits |
3,621 |
2,909 |
|
Professional fees, contractors and consultants |
2,333 |
2,985 |
|
Clinical trial costs |
833 |
148 |
|
Share based payment |
486 |
417 |
|
Office and lab costs |
371 |
676 |
|
Depreciation and amortization |
272 |
294 |
|
Technology costs |
258 |
352 |
|
Travel and entertainment |
113 |
325 |
|
Delivery and logistics |
39 |
48 |
|
Advertising and promotion |
33 |
127 |
|
|
8,359 |
8,281 |
19. Supplementary cash flow information
|
For the six months ended June 30, |
||
|
|
2024 |
2023 |
|
Changes in non-cash working capital items |
|
|
|
Accounts and other receivables |
90 |
84 |
|
Inventory |
(262) |
153 |
|
Prepaid expenses and deposits |
(105) |
(60) |
|
Accounts payable and other liabilities |
296 |
(1,272) |
|
|
19 |
(1,095) |
20. Ultimate controlling party
The Company's CEO is the ultimate controlling party of the Company, personally owning and/or controlling through her personal holding company a total of 40.1% of the issued common shares of the Company as at June 30, 2024 (June 30, 2023 - 55.6%).
On May 9, 2024, as part of the Company's finance raise, 1,825,650 Common Shares and 912,825 warrants were issued to the controlling shareholder.
21. Capital management
The Company's objectives when managing capital are to ensure sufficient liquidity for operations and adequate funding for growth and capital expenditures while maintaining an efficient balance between debt and equity.
The Company's capital consists of items included in shareholders' equity, debt facilities net of cash and restricted cash.
In order to facilitate the management of capital, the Company prepares annual expenditure budgets that are updated as necessary and dependent on various factors, including successful deployment of capital and industry conditions. The annual budgets are approved by the Board of Directors. The Company is not subject to any externally imposed capital requirements.
Management believes that existing cash resources, together with cash generated through operations and funds raised through public or private equity and/or debt financings, will generate sufficient liquidity to meet operating cash requirements for at least the next twelve months.
22. Subsequent events
Subsequent to June 30, 2024, the following transactions had occurred:
1. On September 11, 2024 the Company's controlling shareholder advanced $285 as unsecured, non-interest-bearing with no specific terms of repayment related party loan.
2. On September 23, 2024, the Company has agreed to sell 22,222,222 common shares for $5,000 at a price of $0.225 (GBP0.125). The closing of the transaction is expected to be on or before November 8, 2024.
3. As of September 27, 2024, the Company's controlling shareholder has agreed to provide the company $400 as unsecured, non-interest-bearing with no specific terms of repayment related party loan by the end of September.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 1 day ago Savannah Energy
- 1 day ago Buccaneer Energy PLC
- 1 day ago Savannah Energy
- 1 day ago Carclo
- 1 day ago Schroder Japan Growth Fund